Free Trial

Checkpoint Therapeutics (CKPT) Stock Forecast & Price Target

Checkpoint Therapeutics logo
$3.18 -0.15 (-4.50%)
Closing price 01/17/2025 04:00 PM Eastern
Extended Trading
$3.18 -0.01 (-0.16%)
As of 08:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Checkpoint Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
3

Based on 3 Wall Street analysts who have issued ratings for Checkpoint Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 3 have given a buy rating for CKPT.

Consensus Price Target

$12.00
277.36% Upside
According to the 3 analysts' twelve-month price targets for Checkpoint Therapeutics, the average price target is $12.00. The highest price target for CKPT is $20.00, while the lowest price target for CKPT is $7.00. The average price target represents a forecasted upside of 277.36% from the current price of $3.18.
Get the Latest News and Ratings for CKPT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Checkpoint Therapeutics and its competitors.

Sign Up

CKPT Analyst Ratings Over Time

TypeCurrent Forecast
1/22/24 to 1/21/25
1 Month Ago
12/23/23 to 12/22/24
3 Months Ago
10/24/23 to 10/23/24
1 Year Ago
1/22/23 to 1/22/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
5 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$12.00$13.50$12.00$22.60
Forecasted Upside277.36% Upside260.00% Upside251.91% Upside1,128.26% Upside
Consensus Rating
Buy
Buy
Buy
Buy

CKPT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CKPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Checkpoint Therapeutics Stock vs. The Competition

TypeCheckpoint TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.82
2.52
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside277.36% Upside24,741.16% Upside12.44% Upside
News Sentiment Rating
Neutral News

See Recent CKPT News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/13/2025D. Boral Capital
0 of 5 stars
Jason Kolbert
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00+184.81%
12/16/2024Lake Street Capital
2 of 5 stars
 Boost TargetBuy ➝ Buy$4.00 ➝ $7.00+107.71%
12/16/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00+444.96%
12/20/2023B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$8.00 ➝ $4.00+128.57%
8/15/2023LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$65.00 ➝ $47.00+2,148.79%
8/15/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$19.00 ➝ $14.00+569.85%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 08:54 AM ET.


CKPT Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Checkpoint Therapeutics is $12.00, with a high forecast of $20.00 and a low forecast of $7.00.

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CKPT shares.

According to analysts, Checkpoint Therapeutics's stock has a predicted upside of 277.36% based on their 12-month stock forecasts.

Checkpoint Therapeutics has been rated by research analysts at D. Boral Capital, HC Wainwright, and Lake Street Capital in the past 90 days.

Analysts like Checkpoint Therapeutics more than other "medical" companies. The consensus rating for Checkpoint Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CKPT compares to other companies.


This page (NASDAQ:CKPT) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners